Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13.

Abstract

Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Acrylamides / pharmacology*
  • Alleles*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics*
  • Humans
  • Mutation*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / pharmacology*

Substances

  • Acrylamides
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • ErbB Receptors